

Curriculum Vitae

Edith Caroline (Phoebe) Glazer

John C. Hubbard Professor, College of Arts & Sciences

University of Kentucky
Lexington, KY 40506-0055
Tel: (859) 257-2198

e-mail: ec.glazer@uky.edu

PROFESSIONAL APPOINTMENTS

The University of Kentucky
Assistant Professor, 2009-2015
Associate Professor, 2015-2022
Professor, 2022-present

EDUCATION

- 2004-2009 NIH Postdoctoral fellow, The Scripps Research Institute, La Jolla, CA.
 Advisors: Prof. David B. Goodin and Prof. Harry B. Gray, Caltech.
- 1996-2003 Ph.D. University of California, San Diego.
 Advisor: Prof. Yitzhak Tor
- 1993-1996 BA Williams College, Williamstown, MA.
 Majors in Chemistry and English; *Cum Laude*, Honors in Chemistry
 Advisor: Prof. David P. Richardson
- 1992-1993 Wellesley College, Wellesley, MA.

RESEARCH INTERESTS

- ◆ Light-activated metal complexes as anti-cancer agents
- ◆ Development of assays for cancer drug discovery
- ◆ Structure, function, and dynamics of heme enzymes
- ◆ Photophysics and photochemistry of ruthenium complexes
- ◆ Light-activated probes of protein lifecycle and dynamics
- ◆ DNA structure-selective probes and RNA aptamers

PUBLICATIONS (In reverse chronological order)

At the University of Kentucky: (undergraduate co-authors are underlined; * indicates co-corresponding)

- 1) Havrylyuk, D., Hachey, A.C., Fenton, A., Heidary, D.K., **Glazer, E.C.** “Ru(II) photocages enable precise control over enzyme activity with red light”, *Nat. Commun.* **2022**, 13, 3636-46.
- 2) **Glazer, E.C.**, Casini, A. “Metals in Medicine”, *Eur. J. Inorg. Chem.*, **2022**, e202101093.
- 3) McFarland, S. A., **Glazer, E. C.**, Meorla, J. “Special Editor Preface: Memorial Issue Dedicated to Karen J. Brewer”, *Photochemistry and Photobiology*, **2021**. There are 11 papers in the collection.
- 4) Heidary, D. K. *, Kriger, S. M., Hachey, A. C., **Glazer, E. C.*** “A Fluorometric CYP19A1 (aromatase) activity assay in live cells”, *ChemMedChem*, **2021**, 16, 2845-2850. PMID: 34224206.
- 5) Ryan, R. T., Havrylyuk, D., Stevens, K. C., Moore, L. H., Parkin, S., Blackburn, J. S., Heidary, D. K. *, Selegue, J. P. *, **Glazer, E. C.*** Biological investigations of Ru(II) complexes with diverse β -diketone ligands. **2021**, 35, 3611-3621.
- 6) Hachey, A. C., Havrylyuk, D., **Glazer, E.C.** “Biological activities of polypyridyl type ligands: implications for bioinorganic chemistry and light-activated metal complexes”, *Current Opinion in Chemical Biology*, **2021**, 61, 191-202. PMID: 33799087.

- 7) Zamora, A. *, Wachter, E., Vera, M., Heidary, D.K., Rodríguez, V., Ortega, E., Fernández-Espín, V., Janiak, C., **Glazer, E. C.**, Barone, G. *, Ruiz, J. * “Organoplatinum(II) complexes self-assemble and recognize AT rich duplex DNA sequences”, *Inorg. Chem.*, **2021**, *60*, 2178-87. PMID: 33502194.
- 8) Cole, H.D., Hodges, R., Lifshits, L.M., Roque III, J.A., Barrett, P.C., Cameron, C.G. *, **Glazer, E.C. ***, McFarland, S.A. * “Fine-feature modifications to strained ruthenium complexes radically alter their hypoxic anticancer activity”, *Photochemistry and Photobiology*, **2021**, *96*, 327-39. PMID: 33559191.
- 9) Ryan, R.T. , Havrylyuk, D., Stevens, K.C., Moore, L.H., Kim, D.Y., Blackburn, J.S.*, Heidary, D.K.*, Selegue, J.P.* , **Glazer, E.C.*** “Avobenzonone incorporation in a diverse range of Ru(II) scaffolds produces potent potential antineoplastic agents”, *Dalton Trans.*, **2020**, *49*, 12161-12167. PMID: 32845256.
- 10) Havrylyuk, D. *, Heidary, D.K., Sun, Y., Parkin, S., **Glazer, E.C.*** “Photochemical and photobiological properties of pyridyl-pyrazol(in)e-based ruthenium(II) complexes with sub-micromolar cytotoxicity for phototherapy”, *ACS Omega*, **2020**, *5*, 18894-18906. PMID: 32775891.
- 11) Ryan, R.T., Stevens, K.C., Calabro, R., Parkin, S., Mahmoud, J., Kim, D.Y., Heidary, D.K., **Glazer, E.C.***, Selegue, J.P.* “Bis-tridentate N-Heterocyclic Carbene Ru(II) complexes are promising new agents for photodynamic therapy”, *Inorg. Chem.*, **2020**, *59*, 8882-8892. PMID: 32530274.
- 12) Havrylyuk, D., Stevens, K., Parkin, S., **Glazer, E. C.** “Towards optimal Ru(II) photocages: balancing photochemistry, stability, and biocompatibility through fine tuning of steric, electronic, and physicochemical features”, *Inorg. Chem.*, **2020**, *59*, 1006-13. PMID: 31899619.
- 13) Roque, J., Havrylyuk, D., Barrett, P. C., Sainuddin, T., McCain, J., Colón, K., Sparks, W. T., Bradner, E., Monro, S., Heidary, D. K., Cameron, C., **Glazer, E. C.***, McFarland, S. A. * “Strained, photoejecting Ru(II) complexes that are cytotoxic under hypoxic conditions”, *Photochemistry and Photobiology*, **2020**, *96*, 327-339. PMID: 31691282.
- 14) Havrylyuk, D., Deshpande, M., Parkin, S., **Glazer, E. C.** “Ru(II) complexes with diazine ligands: electronic modulation of coordinating group is key to the design of “dual action” photoactivated agents”, *ChemComm*, **2018**, *54*, 12487-90. PMID: 30338772.
- 15) Geranimo, I., Denning, C. A., Heidary, D. K., **Glazer, E. C.***, Payne, C.* “Molecular determinants of small molecule affinity and activity of a cytochrome P450BM3 variant”, *Biophysical Journal*, **2018**, *115*, 1251-63. PMID: 30224054.
- 16) Pillar-Little, T. J., Wanninayake, N., Nease, L., Heidary, D. K., **Glazer, E. C. ***, Kim, D. Y.* “Superior photodynamic effect of carbon quantum dots through both type I and type II pathways: Detailed comparison study of top-down-synthesized and bottom-up-synthesized carbon quantum dots”, *Carbon*, **2018**, *140*, 612-23.
- 17) Sun, Y., Heidary, D. K., Zhang, Z., Richards, C., **Glazer, E. C.** “Bacterial cytological profiling reveals the mechanism of action of anticancer metal complexes”, *Molecular Pharmaceutics*, **2018**, *15* (8), pp 3404-16. PMID: 29865789. *ACS Editor's Choice*.
- 18) Havrylyuk, D., Howerton, B. S., Nease, L. A., Parkin, S., Heidary, D. K., **Glazer, E. C.** “Structure-activity relationships of anticancer ruthenium(II) complexes with substituted hydroxyquinolines”, *European J. Med. Chem.*, **2018**, *156*, 790-99. PMID: 30055464.
- 19) Kohler, L., Nease, L. A., Vo, P., Garofolo, J., Heidary, D. K., Thummel, R. P.* , **Glazer, E. C.*** “Photochemical and photobiological activity of Ru(II) homoleptic and heteroleptic complexes containing methylated bipyridyl-type ligands”, *Inorg. Chem.* **2017**, *56*, 12214-23. PMID: 28949518.
- 20) **Glazer, E. C.** “Panchromatic osmium complexes for photodynamic therapy: solutions to existing problems and new questions”, *Photochem. Photobiol.* **2017**, *93*, 1326-28 (*Invited Review*). PMID: 28543667.
- 21) Zamora, A., Denning, C. A., Heidary, D. K., Wachter, E., Nease, L. A., Ruiz, J., **Glazer, E. C.** “Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage”, *Dalton Tans.* **2017**, *46*, 2165-2173. PMID: 28121322.
- 22) Havrylyuk, D., Heidary, D. K., Nease, L. A., **Glazer, E. C.** “Photochemical properties and structure-activity relationships of Ru(II) complexes with pyridyl-benzazole ligands as promising anticancer agents”, *European Journal of Inorganic Chemistry*, **2017**, *12*, 1687-94. PMID: 29200939. *Very Important Paper; Back Cover*.

- 23) Heidary, D., Fox, A., Richards, C., **Glazer, E. C.** “A high-throughput screening assay using a photoconvertible protein for identifying inhibitors of transcription, translation, or proteasomal degradation”, *SLAS Discovery*, **2017**, 22, 4, 399-407. PMID: 28328316.
- 24) Wachter, E., Moya, D., **Glazer, E. C.** “Combining a Ru(II) “building block” and rapid screening approach to identify DNA structure-selective “light switch” compounds” *ACS Combinatorial Science*, **2017**, 19 (2), 85-95. PMID: 28029775. *Front Cover*.
- 25) Wachter, E., Zamora, A., Heidary, D. K., Ruiz, J., **Glazer, E. C.** “Geometry matters: inverse cytotoxic relationship for cis/trans-Ru(II) polypyridyl complexes from cis/trans-[PtCl₂(NH₃)₂]” *ChemComm*, **2016**, 52, 1021-24. PMID: 27352966. *Back Cover*.
- 26) Geronimo, I., Denning, C. A., Rogers, W. E., Othman, T., Huxford, T., Heidary, D. K., **Glazer, E. C., Payne, C. M.** “Effect of mutation and substrate binding on the stability of Cytochrome P450_{BM3} variants”, *Biochemistry*, **2016**, 55, 3594-606. PMID: 27267136.
- 27) Wachter, E., **Glazer, E. C.**, Parkin, S., Brock, C. P. “An exceptional 5:4 enantiomeric structure” *Acta Cryst. B* **2016**, B72, 223-31. PMID: 27048724.
- 28) Dickerson, M., Howerton, B. S., Bae, Y., **Glazer, E. C.** “Light-sensitive ruthenium complex-loaded cross-linked polymeric nanoassemblies for the treatment of cancer” *J. Materials Chem. B*. **2016**, 4, 394-408. PMID: 25249443. *Hot Paper*.
- 29) Wachter, E., Moya, D., Parkin, S., **Glazer, E. C.** “Ruthenium complex “light switches” that are selective for different G-quadruplex structures” *Chem. Eur. J.* **2016**, 22, 550-9. PMID: 26560887. Identified as *Hot Paper*, *Back Cover*.^{§§}
- 30) Magde, D.,* Magde, M. D., **Glazer, E. C.** “So-called “Dual Emission” for ³MLCT luminescence in ruthenium complex ions: What is really happening?” *Coord. Chem. Rev.* **2016**, 306, 2, 447-467. (D. Magde was corresponding author. Included in a special issue dedicated to Peter Ford).
- 31) Heidary, D. K., Howerton, B.S., **Glazer, E. C.** “Coordination of quinolines to ruthenium bis-dimethyl-phenanthroline improves potency for potential antineoplastic agents”, *J. Med. Chem.* **2014**, 57, 8936-8946. PMID: 25314373.
- 32) Hidayatullah, A. N., Wachter, E., Heidary, D. K., Parkin, S., **Glazer, E. C.** “Photoactive Ru(II) complexes with dioxinophenanthroline ligands are potent cytotoxic agents”, *Inorg. Chem.* **2014**, 53, 10030-10032. PMID: 25198057.
- 33) Dickerson, M., Sun, Y., **Glazer, E. C.** “Modifying charge and hydrophilicity of simple Ru(II) polypyridyl complexes radically alters biological activities: old complexes, surprising new tricks”, *Inorg. Chem.* **2014**, 53, 10370-10377. PMID: 25249443.
- 34) Wachter, E., **Glazer, E. C.** “Mechanistic study on the photochemical “light-switch” behavior of [Ru(bpy)₂dmdppz]²⁺”, included in the special issue “Current Topics in Photochemistry” in *J. Phys. Chem. A* **2014**, 45, 10474-10486. PMID: 25058448.
- 35) Heidary, D. K., **Glazer, E. C.** “A light-activated metal complex targets both DNA and RNA in a fluorescent in vitro transcription and translation assay”, *ChemBioChem* **2014**, 15, 507-511. PMID: 24482049.
- 36) Wachter, E., Howerton, B. S., Hall, E. C., Parkin, S. **Glazer, E. C.** “A new type of DNA “light-switch”: a dual photochemical sensor and metalating agent for duplex and G-quadruplex DNA”, *ChemComm* **2014**, 50, 311-313. PMID: 24226814.
- 37) **Glazer, E. C.** “Light-activated metal complexes that covalently modify DNA”, invited review, *Israel Journal of Chemistry* special issue on “Contemporary Topics in Nucleic Acids”; **2013**, 53, 391-400.
- 38) Wachter, E., Heidary, D. K., Howerton, B. S., **Glazer, E. C.** “Light-activated ruthenium complexes photobind DNA and are cytotoxic in the photodynamic therapy window”, *ChemComm* **2012**, 48, 9649-9651. PMID: 22908094.
- 39) Howerton, B. S., Heidary, D. K., **Glazer, E. C.** “Strained ruthenium complexes are potent light-activated anticancer agents”, *J. Am. Chem. Soc.* **2012**, 134, 8324-8327.** PMID: 22553960.
- 40) **Glazer, E. C.**[#], Lee, Y. T.[#], Wilson, R. F., Stout, C. D., and Goodin, D. B. “Three clusters of conformational states in P450cam reveals a multi-step pathway for opening of the substrate access channel”, *Biochemistry* **2011**, 50, 693-703. PMID: 21171581. [#]Equal contribution.

Other Publications:

- 41) **Glazer, E. C.**, Nguyen, Y. H., Goodin, D. B., Gray, H.B. “Probing inducible nitric oxide synthase with a pterin-Ru(II) sensitizer wire”, *Angew. Chem.* **2008**, *47*, 898-901.
- 42) **Glazer, E. C.**, Magde, D., Tor, Y. “Ru(II) complexes that break the rules: structural features regulating dual emission”, *J. Am. Chem. Soc.* **2007**, *129*, 8544-8551.
- 43) Contakes, S. M., Nguyen, Y. H., Gray, H. B., **Glazer, E. C.**, Hays, A. M., Goodin, D. B. “Conjugates of heme-thiolate enzymes with photoactive metal-diimine wires”, *Structure and Bonding*, **2007**, *123*, 177-203.
- 44) Jouvenot, D., **Glazer, E. C.**, Tor, Y. “Photodimerizable ditopic ligand”, *Org. Lett.* **2006**, *8*, 1987-1990.
- 45) Udit, A. K., Belliston-Bittner, W., **Glazer, E. C.**, Nguyen, Y. H., Gillan, J. M., Hill, M. G., Marletta, M. A., Goodin, D. B., Gray, H. B. “Redox couples of inducible nitric oxide synthase”, *J. Am. Chem. Soc.* **2005**, *127*, 11212-3.
- 46) **Glazer, E. C.**, Belyea, B., Tor, Y. “A simple synthesis of isotopically pure 2,2'-bipyridyl-*d*₈”, *Inorg. Chem. Comm.* **2005**, *8*, 517-519.
- 47) **Glazer, E. C.**, Magde, D., Tor, Y. “Dual emission from a family of conjugated dinuclear Ru^{II} complexes”, *J. Am. Chem. Soc.* **2005**, *127*, 4190-4192.
- 48) Aldrich-Wright, J., Brodie, C., **Glazer, E. C.**, Luedtke, N. W., Elson-Schwab, L., Tor, Y. “Symmetrical bisintercalating complexes based on [Ru(dpq)₂(phen)]²⁺ with high DNA affinity”, *Chem. Comm.* **2004**, *8*, 1018-1019.
- 49) **Glazer, E. C.**, Tor, Y. “Ru(II) complexes of "large-surface" ligands”, *Angew. Chem.* **2002**, *41*, 4022-4026.
- 50) Luedtke, N. W., Hwang, J. S., **Glazer, E. C.**, Gut, D., Kol, M., Tor, Y. “Eilatin Ru(II) complexes display anti-HIV activity and enantiomeric diversity in the binding of RNA”, *ChemBioChem* **2002**, *3*, 766-771.
- 51) **Glazer, E. C.**, Tor, Y. “Chiral metal-containing polymers”, *Polymer Preprints* **1999**, *40*, 513-514.
- 52) Diaz-Garcia, M. A., Wright, D., Casperson, J. D., **Smith, B.**, **Glazer, E.**, Moerner, W. E., Sukhomlinova, L. I., Twieg, R. J. “Photorefractive properties of poly(N-vinyl carbazole)-based composites for high-speed applications”, *Chemistry of Materials* **1999**, *11*, 1784-1791.

Book Chapters:

- 1) Havrylyuk, D., Hachey, A.C., **Glazer, E.C.**, “Light-Activated Drugs for Photodynamic Therapy”, Book Chapter in *Metal Ions in Life Sciences Volume 24, “Targeted Metallo-Drugs: Design, Development, and Mode of Action”*, Guest-edited by Etelka Farkas and Celine J. Marmion.

PATENTS AND OTHER RESEARCH RELATED ACCOLADES

***JACS communication* 2012 Highlighted in *Chemical and Engineering News*, “Turning on ruthenium to kill cancer cells”, *Science and Technology, Latest News*, May 9, 2012; “Ruthenium switches on to kill cancer cells”, *Science and Technology, Concentrates*, May 21, 2012; highlighted on several medical websites.**

##*ChemBioChem paper* 2014 Highlighted on the Thermo Fisher website as an application of the Pierce Human *In Vitro* Protein Expression system.

\$\$ *Chem. Eur. J. paper* 2016 Highlighted on *ScienceDaily* and other websites.

“Light-activated compounds”, U.S. Patent No. 9,290,528, issued 3/22/2016.

“Potent and selective CYP1B1 inhibitors”, U.S. Provisional Patent, full patent application filed 2/11/2021.

GRANTS RECEIVED

Current:

- 1) Co-PI, with Jessica Blackburn, PI, “Analysis and Targeting of the Transcriptional Regulator BRD4 in Diffuse Intrinsic Pontine Glioma (DIPG)”, Kentucky Pediatric Cancer Research Trust Fund, \$604,354, July, 2022-June, 2024.
- 2) Contact PI, Three-PI grant (with Heidary, Richards), “Role of small molecule interactions and multiprotein assemblies in CYP1B1 disease-associated function and dysfunction”, National Institutes of Health, National Institute of General Medical Sciences, 1R01GM138882, \$1439,783, September, 2020–August, 2024.

- 3) Supplement to 1R01GM138882 to investigate the role of CYP1B1 in cerebrovascular function in neurodegenerative diseases; \$334,471, August, 2021–July, 2022. Contact PI, four PI supplement (with Heidary, Johnson, and Richards).
- 4) Supplement to 1R01GM138882 for instrumentation, \$124,565, August, 2021–July, 2022. Contact PI, two PI supplement (with Heidary).
- 5) PI, Two-PI grant (with Heidary), “Inorganic-aptamer hybrids for live cell imaging”, National Science Foundation, CHE 2002956, \$372,000, August 2020–July 2023.

Completed:

- 1) PI, “Metals in Medicine Gordon Research Conference”, National Institutes of Health, \$10,000, June, 2020 (delayed to 2022).
- 2) Co-PI, one of 24, NIH-COBRE, Jon Thorson, PI. \$11,200,000, December, 2019–November, 2024, 0.5 months effort dedicated.
- 3) PI, “Light-responsive ruthenium compounds for applications in disease”, National Institutes of Health, Supplement, R01GM107586, \$259,360, August 2019-September, 2021.
- 4) PI, “Metals in Medicine Gordon Research Conference”, National Institutes of Health, \$15,000, June, 2018.
- 5) Co-PI, “Cytotoxic Photoactive Ruthenium(II) Complexes with Polypyridyl and N-Heterocyclic Carbene Ligands”, Kentucky Science and Technology Co, \$50,000, July 2017–August 2019.
- 6) Co-PI, “MRI: Acquisition of a single-crystal diffractometer for chemistry and materials research”, National Science Foundation, \$268,193 August 2016–July 2019.
- 7) PI, “Light-responsive ruthenium compounds for applications in disease”, National Institutes of Health, \$1,412,735, August, 2014-July, 2019.
- 8) Contributing Investigator, “Powering the Kentucky bioeconomy for a sustainable future”, National Science Foundation, \$20,000,000, July 2014–June 2019.
- 9) PI, “Ruthenium complex scaffolds for the creation of targeted chemotherapeutics,” American Cancer Society Research Scholar Grant, \$715,000, January 2013-December 2016.
- 10) PI, “Light-activated ruthenium complexes as a new class of selective and modular chemotherapeutic agents,” Pardee Foundation, \$118,000, March 2011-May 2012.
- 11) PI, “Photo-active ruthenium complexes as selective, modular metallo-chemotherapeutics,” American Cancer Society Institutional Research Grant, \$15,000, July 2010-June 2011.

TRAINING FACULTY MEMBER

- 1) University of Kentucky Cancer Nanotechnology Training Center (supported by the NCI/NIH and part of the National Cancer Institute Alliance for Nanotechnology in Cancer (5R25CA153954)).
- 2) University of Kentucky “Training in Drug Abuse Related Research” (supported by NIDA/NIH T32 DA016176).
- 3) Mentor in the UK Center of Biomedical Research Excellence (COBRE) in Pharmaceutical Research and Innovation (CPRI) (supported by NIGMS/NIH 1P20GM130456).

TEACHING EXPERIENCE

University of Kentucky:

Fall, 2009-present

- ◆ Biological Chemistry II (CHE 552).
- ◆ DNA Structure, Damage, and Cancer (CHE 580); this was a new specialty course.
- ◆ Advanced Inorganic Chemistry (CHE 510).
- ◆ Sophomore Organic Chemistry (CHE 230-002, 230 student class size).
- ◆ Biological Chemistry Seminar (CHE 776)

- ◆ Graduate Chemistry Seminar (CHE 776); this is a new 3 credit specialty course focused on scientific communication.
- ◆ Guest Lecturer, Biochemistry I (CHE 550), Pharmaceutical Science (PHS 633)

University of California, San Diego, La Jolla, California:

Lecturer, Winter, 2008-Spring, 2009

- ◆ Taught Sophomore Organic Chemistry (Chem 140A and 140B, 350 student class size). Developed the curriculum and taught an Introductory Chemistry for non-majors (Chem 15).

PROFESSIONAL ACTIVITIES

Memberships: American Chemical Society, American Association for Cancer Research, Inter-American Photochemical Society, American Society for Photobiology, Association for Women in Science, Sigma Xi
Reviewer, Journals: Nature Chemistry, Angewandte Chemie, Journal of the American Chemical Society, Inorganic Chemistry, Bioconjugate Chemistry, Journal of Inorganic Biochemistry, Bioorganic and Medicinal Chemistry, ChemMedChem, ChemComm, Organometallics, Chemical Science
Guest Editor: 2021 ChemMedChem & European Journal of Inorganic Chemistry *Special Issue on Metals in Medicine*; 2021 Photochemistry and Photobiology *Memorial Issue of in honor of Karen Brewer*.

SERVICE

Departmental:

Graduate Student Recruitment Committee	2009-2013, 2018
Graduate Program Committee	2010-2011
Faculty Search Committee	2010-11, 2015-16
Seminar Committee	2011-2014
Chair, Naff Symposium	2011-2012
Biological Chemistry Cumulative Exam Coordinator	2012-2015, 2016-2017
Chair, Undergraduate Poster Competition	2013-2014
Building and Safety Committee	2014-2015
Awards Committee, Chair	2014-2017
Faculty Advisor for the Society of Postdoctoral Scholars	2015-present
Website Committee	2015-2018
Executive Committee	2016-2018, 2019-present
DEI (Diversity, Equity, and Inclusion) Committee	2020-present

College:

Staff Faculty Collegiality Committee	2015-2018
Research and Scholarship Strategic Plan Implementation Committee	2016

University wide:

RFP Committee for Scientific Purchasing	2011-2015
Research and Scholarship Strategic Plan Implementation Committee	2015-2016
Institutional Reviewer, American Cancer Society	2016-present
College of Pharmacy Faculty Search	2018
FCIM SRF Scientific Advisory Committee	2019-present

National:

ACS National Award Selection Committee (2023-2025 award cycle)	2022-present
Co-Chair, 2 nd International Symposium on Clinical and Experimental Metallodrugs in Medicine	2020-2021
Chair, Gordon Research Conference on Metals in Medicine	2018-2022
Vice-Chair, Gordon Research Conference on Metals in Medicine	2016-2018
National Academies of Science, Engineering and Medicine	
NRC Research Associateship Chemistry Program Co-Chair	2020-present
NRC Program Reviewer	2016-present
NIH Reviewer, ZRG1 CB-P(55) MIRA	2020, 2021, 2022

NIH Reviewer, BCMB (Ad hoc)	2018
NIH Reviewer, CSR Anonymization Study	2018
NIH Reviewer, SBCA (Ad hoc)	2018
NIH Reviewer, RTB Study Section (Ad hoc)	2015-2017
NSF Study Section Member	2016-2018
ACS Biological Division Program Committee Chair-elect	2020-present
ACS Inorganic Division Member at Large	2018-present
ACS Bioinorganic Subdivision Chair	2016-2017
Session Moderator, Gordon Research Conference on Metals in Medicine	2016
Advisory Board, Chemical Society Reviews	2016-2018

INVITED TALKS (Contributed talks are not included)

Colleges and Universities:

San Diego State University, Bowling Green State University, Ohio University, West Virginia State University, West Virginia Tech, University of Iowa, Purdue University, University of California, San Diego, The Scripps Research Institute, California Institute of Technology, California State University, Los Angeles, University of Texas, Arlington, Virginia Tech, University of British Columbia, Simon Fraser University, University of Alabama, Medical University of South Carolina, Trinity University, University of Murcia, Spain, The Ohio State University, University of Dayton, University of Texas, Arlington.

Conferences:

20th International Symposium on the Photophysics and Photochemistry of Coordination Compounds, July 2013; 23rd Inter-American Photochemical Society Meeting, January, 2014; Gordon Research Conference on Metals in Medicine, invited seminar in the “New Frontiers: Early Career Investigators Selected from Abstracts” section, June, 2014. 2015: National ACS Meeting, March, 2015, Pacificchem, December, 2015, American Society for Photobiology, May, 2016, 42nd International Conference on Coordination Chemistry, July, 2016; Summer School on Photochemistry at the Holland Research School of Molecular Chemistry, 2016; Photopharmacology Symposium at the University Medical Center Groningen, The Netherlands, 2017; CanBIC, Perry Sound, Canada, 2017; Symposium on The Triplet Excited State in Inorganic Chemistry, National ACS Meeting, 2017; American Society for Photobiology, May, 2018, EuroBIC, June, 2018; 2nd International Symposium on Photopharmacology, November, 2018, CanBIC, Perry Sound, Canada, 2019, Ohio Photochemistry Symposium, Maumee Bay, OH 2019, Inorganic Chemistry 19, Wollongong, Australia, 2019, 2nd Frontiers in Photochemistry Conference, Nassau, Bahamas, 2020, American Chemical Society National Meeting, San Diego, CA, March, 2022, 28th PhotoIUPAC Meeting, Amsterdam, Netherlands, July, 2022, Keynote Lecture 44th International Conference on Coordination Chemistry, Rimini, Italy, August, 2022.

COMMITMENT TO DIVERSITY AND INCLUSION

I am strongly committed to creating an inclusive and diverse community within my laboratory, my department, and the college. This has been implemented through active recruitment of members of underrepresented groups in science and providing training in recognizing and overcoming bias in both the classes I teach and my mentoring interactions. The students and scientists in the Glazer Laboratory have been 60% female and 25% members of minority groups. Furthermore, I work to support and increase the diversity of my research community through my efforts in conference organization, grant and fellowship review, and organizational self-studies, such as the NIH study of the effect of anonymization on grant review. In addition, I worked to establish the Chemistry Department DEI (Diversity, Equity, and Inclusion) Committee in 2020, and serve as a member.